WeWork founder donates $1 million to help find bone marrow donors

This post was originally published on this site
Inside WeLive's NYC apartments

Inside WeLive’s NYC apartments

WeWork CEO Adam Neumann has been calling on employees to get their mouths swabbed for months.

Neumann and Rebekah Paltrow Neumann, his wife and founding partner, have been trying to find a bone marrow match for one of the company’s earliest employees, Valerie Batista. Batista joined WeWork in 2011 as its 15th employee.

At that point, WeWork was a fledgling startup trying to get coworking spaces off the ground. Today, it’s valued at nearly $17 billion. It has 140 coworking communities in 15 countries, and is dabbling in shared housing.

Batista moved through the ranks at WeWork, from an assistant community manager to national sales director. But she’s been on leave since last spring, when she was diagnosed with a bone marrow disease known as severe aplastic anemia.

“She didn’t tell anyone how severe it was,” said Neumann.

wework be the match
Rebekah Paltrow Neumann, Valerie Batista and Adam Neumann

Batista, who is 35, is one of roughly 12,000 people each year who need a bone marrow transplant to treat life-threatening diseases, like leukemia or sickle cell anemia. Finding a match can be incredibly difficult; It typically requires ethnic compatibility between donor and patient. Batista is Mexican-American, which makes it even harder for her to find a match.

Neumann said he only realized how dire Batista’s situation was in December, when she reached out to WeWork’s legal counsel for advice on putting together her last will and testament. After two failed matches, Batista said she had resigned herself to dying; she’d even stopped taking her medication. That’s when Neumann ramped up his efforts.

Neumann and cofounder Miguel McKelvey circulated a moving video in December among employees, detailing their mission to find a match for Batista.

“Something snapped in my head when I saw Adam talking,” Batista said this week. “It was like a huge weight came off my shoulders. I thought, ‘I’ll let Adam find the match. And I’ll just worry about getting better.'”

Related: WeWork launches in Shanghai

WeWork partnered with Be the Match, the largest and most diverse bone marrow transplant registry in the world, to host seven registration drives in the U.S., Israel and the UK. It plans to host events in Amsterdam and Australia this month.

The Neumanns are personally donating $1 million to Be the Match to help bolster the organization’s efforts, in the hopes of raising awareness and expanding the registry’s reach. It’s a significant donation for the organization, which it said is about 12% of its annual contributions.

In addition to the money, WeWork is partnering with the nonprofit to share talent from its data resources, salesforce and communications team. Be the Match is currently only meeting about half of the demand in the U.S., facilitating about 6,000 bone marrow and cord blood transplants a year from donors around the world.

Related: Why adults are embracing coliving

Be the Match has 19 million potential donors in its database, according to its CEO, Dr. Jeffrey Chell. Many are called years after they’ve swabbed, if at all. There are two types of procedures, one of which is non-surgical.

So far, 1,000 WeWork employees and members have registered their DNA with Be the Match and entered the database as potential matches for others like Batista.

“We need young, healthy, ethnically diverse people to join the registry and together we can save thousands of more lives each year,” said Be the Match CEO Dr. Jeffrey Chell.

Batista met the Neumanns while working as a real estate broker in 2011. She showed them an apartment, which the pair recalls as being too expensive for their budget. But they were convinced that Batista needed to join their startup.

“We have an approach, in general, which is when we see people just doing their work, doing a phenomenal job, we often find those are some of the best people to bring into the company,” said Paltrow Neumann. “They don’t have an agenda, they’re just being authentically good at what they’re doing.”

“[Batista] has a light that she radiates,” Paltrow Neumann said. “It’s tenacity mixed with grace and a smile.”

Batista said that after viewing Neumann and McKelvey’s video in December, she began taking her medicine again. And she’s noticed a mental difference in herself.

“I’m overflowing with gratitude and love. Adam changed my life twice really — but that was the time that I think he really saved it. I had really given up.”

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.